{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:55:43Z","timestamp":1783742143039,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11427-022-2173-9","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T11:04:00Z","timestamp":1666004640000},"page":"754-770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Loop CD20\/CD19 CAR-T cells eradicate B-cell malignancies efficiently"],"prefix":"10.1007","volume":"66","author":[{"given":"Zhaoqi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianci","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"2173_CR1","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina, A., and Maher, J. (2018). Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther 17, 1795\u20131815.","journal-title":"Mol Cancer Ther"},{"key":"2173_CR2","doi-asserted-by":"publisher","first-page":"10638","DOI":"10.18632\/oncotarget.7079","volume":"7","author":"N An","year":"2016","unstructured":"An, N., Tao, Z., Li, S., Xing, H., Tang, K., Tian, Z., Rao, Q., Wang, M., and Wang, J. (2016). Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. Oncotarget 7, 10638\u201310649.","journal-title":"Oncotarget"},{"key":"2173_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews, L.P., Marciscano, A.E., Drake, C.G., and Vignali, D.A.A. (2017). LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276, 80\u201396.","journal-title":"Immunol Rev"},{"key":"2173_CR4","doi-asserted-by":"publisher","unstructured":"Bar, L., Nguyen, C., Galibert, M., Santos-Schneider, F., Aldrian, G., Dejeu, J., Lartia, R., Coche-Gu\u00e9rente, L., Molina, F., and Boturyn, D. (2021). Determination of the Rituximab Binding Site to the CD20 Epitope Using SPOT Synthesis and Surface Plasmon Resonance Analyses. Anal Chem, https:\/\/doi.org\/10.1021\/acs.analchem.1c00960.","DOI":"10.1021\/acs.analchem.1c00960"},{"key":"2173_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/1566524024605671","volume":"2","author":"S Baumann","year":"2002","unstructured":"Baumann, S., Krueger, A., Kirchhoff, S., and Krammer, P.H. (2002). Regulation of T cell apoptosis during the immune response. Curr Mol Med 2, 257\u2013272.","journal-title":"Curr Mol Med"},{"key":"2173_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/leu.2017.302","volume":"32","author":"KH Chen","year":"2018","unstructured":"Chen, K.H., Wada, M., Pinz, K.G., Liu, H., Shuai, X., Chen, X., Yan, L.E., Petrov, J.C., Salman, H., Senzel, L., et al. (2018). A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia 32, 402\u2013412.","journal-title":"Leukemia"},{"key":"2173_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibri\u00e1n","year":"2017","unstructured":"Cibri\u00e1n, D., and S\u00e1nchez-Madrid, F. (2017). CD69: from activation marker to metabolic gatekeeper. Eur J Immunol 47, 946\u2013953.","journal-title":"Eur J Immunol"},{"key":"2173_CR8","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.3390\/ijms22147652","volume":"22","author":"M Cosenza","year":"2021","unstructured":"Cosenza, M., Sacchi, S., and Pozzi, S. (2021). Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci 22, 7652.","journal-title":"Int J Mol Sci"},{"key":"2173_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg, M.S., Walshe, C.A., Ivanov, A.O., and Glennie, M.J. (2005). The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8, 140\u2013174.","journal-title":"Curr Dir Autoimmun"},{"issue":"1","key":"2173_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1182\/asheducation-2015.1.400","volume":"2015","author":"DJ DeAngelo","year":"2015","unstructured":"DeAngelo, D.J. (2015). The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. Hematology 2015 (1), 400\u2013405.","journal-title":"Hematology"},{"key":"2173_CR11","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","volume":"112","author":"MN Dworzak","year":"2008","unstructured":"Dworzak, M.N., Schumich, A., Printz, D., P\u00f6tschger, U., Husak, Z., Attarbaschi, A., Basso, G., Gaipa, G., Ratei, R., Mann, G., et al. (2008). CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 112, 3982\u20133988.","journal-title":"Blood"},{"key":"2173_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J., Sun, J., Eyquem, J., Ho, Y.J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., and Sadelain, M. (2019). Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25, 82\u201388.","journal-title":"Nat Med"},{"key":"2173_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1034\/j.1600-065X.2003.00051.x","volume":"193","author":"DR Green","year":"2003","unstructured":"Green, D.R., Droin, N., and Pinkoski, M. (2003). Activation-induced cell death in T cells. Immunol Rev 193, 70\u201381.","journal-title":"Immunol Rev"},{"key":"2173_CR14","doi-asserted-by":"publisher","first-page":"1825177","DOI":"10.1080\/2162402X.2020.1825177","volume":"9","author":"S Grote","year":"2020","unstructured":"Grote, S., Mittelstaet, J., Baden, C., Chan, K.C.H., Seitz, C., Schlegel, P., Kaiser, A., Handgretinger, R., and Schleicher, S. (2020). Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. OncoImmunology 9, 1825177.","journal-title":"OncoImmunology"},{"key":"2173_CR15","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo, Y., Xie, Y.Q., Gao, M., Zhao, Y., Franco, F., Wenes, M., Siddiqui, I., Bevilacqua, A., Wang, H., Yang, H., et al. (2021). Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity. Nat Immunol 22, 746\u2013756.","journal-title":"Nat Immunol"},{"key":"2173_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M., Dobrin, A., Cabriolu, A., van der Stegen, S.J.C., Giavridis, T., Mansilla-Soto, J., Eyquem, J., Zhao, Z., Whitlock, B.M., Miele, M.M., et al. (2019). CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116.","journal-title":"Nature"},{"key":"2173_CR17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso, W., Lee, D.W., Shah, N.N., Stetler-Stevenson, M., Yuan, C.M., Pastan, I.H., Dimitrov, D.S., Morgan, R.A., FitzGerald, D.J., Barrett, D. M., et al. (2013). Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165\u20131174.","journal-title":"Blood"},{"key":"2173_CR18","doi-asserted-by":"publisher","first-page":"22351","DOI":"10.1073\/pnas.2010229117","volume":"117","author":"S Kang","year":"2020","unstructured":"Kang, S., Tanaka, T., Inoue, H., Ono, C., Hashimoto, S., Kioi, Y., Matsumoto, H., Matsuura, H., Matsubara, T., Shimizu, K., et al. (2020). IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci USA 117, 22351\u201322356.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2173_CR19","first-page":"e16307","volume":"13","author":"B Kanwal","year":"2021","unstructured":"Kanwal, B. (2021). Relapsed\/Refractory non-hodgkin lymphoma: engineering T-cells to express chimeric antigen receptors (CARs), a salvage? Cureus 13, e16307.","journal-title":"Cureus"},{"key":"2173_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.omto.2021.03.001","volume":"20","author":"H Kubo","year":"2021","unstructured":"Kubo, H., Yagyu, S., Nakamura, K., Yamashima, K., Tomida, A., Kikuchi, K., Iehara, T., Nakazawa, Y., and Hosoi, H. (2021). Development of non-viral, ligand-dependent, EPHB4-speciffic chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol Ther-Oncol 20, 646\u2013658.","journal-title":"Mol Ther-Oncol"},{"key":"2173_CR21","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/eji.202049064","volume":"51","author":"AG Levin","year":"2021","unstructured":"Levin, A.G., Rivi\u00e8re, I., Eshhar, Z., and Sadelain, M. (2021). CAR T cells: building on the CD19 paradigm. Eur J Immunol 51, 2151\u20132163.","journal-title":"Eur J Immunol"},{"key":"2173_CR22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/hum.2017.241","volume":"29","author":"S Li","year":"2018","unstructured":"Li, S., Tao, Z., Xu, Y., Liu, J., An, N., Wang, Y., Xing, H., Tian, Z., Tang, K., Liao, X., et al. (2018). CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype. Hum Gene Ther 29, 626\u2013639.","journal-title":"Hum Gene Ther"},{"key":"2173_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R.G., and Mackall, C.L. (2018). Tumor antigen escape from CAR T-cell therapy. Cancer Discovery 8, 1219\u20131226.","journal-title":"Cancer Discovery"},{"key":"2173_CR24","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.3390\/ijms22115536","volume":"22","author":"V Mancikova","year":"2021","unstructured":"Mancikova, V., and Smida, M. (2021). Current state of CAR T-cell therapy in chronic lymphocytic leukemia. Int J Mol Sci 22, 5536.","journal-title":"Int J Mol Sci"},{"key":"2173_CR25","doi-asserted-by":"publisher","first-page":"681984","DOI":"10.3389\/fimmu.2021.681984","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi, F., Rahman, H.S., Achmad, M.H., Sergeevna, K.N., Suksatan, W., Abdelbasset, W.K., Mikhailova, M.V., Shomali, N., Yazdanifar, M., Hassanzadeh, A., et al. (2021). A deep insight into CAR-T cell therapy in non-hodgkin lymphoma: application, opportunities, and future directions. Front Immunol 12, 681984.","journal-title":"Front Immunol"},{"key":"2173_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1089\/hum.2017.126","volume":"28","author":"A Martyniszyn","year":"2017","unstructured":"Martyniszyn, A., Krahl, A.C., Andr\u00e9, M.C., Hombach, A.A., and Abken, H. (2017). CD20-CD19 bispecific CAR T cells for the treatment of B-cell malignancies. Hum Gene Ther 28, 1147\u20131157.","journal-title":"Hum Gene Ther"},{"key":"2173_CR27","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.20.03458","volume":"39","author":"RM Myers","year":"2021","unstructured":"Myers, R.M., Li, Y., Barz Leahy, A., Barrett, D.M., Teachey, D.T., Callahan, C., Fasano, C.C., Rheingold, S.R., DiNofia, A., Wray, L., et al. (2021). Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 39, 3044\u20133055.","journal-title":"J Clin Oncol"},{"key":"2173_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/ph13090244","volume":"13","author":"N Nistic\u00f2","year":"2020","unstructured":"Nistic\u00f2, N., Maisano, D., Iaccino, E., Vecchio, E., Fiume, G., Rotundo, S., Quinto, I., and Mimmi, S. (2020). Role of chronic lymphocytic leukemia (CLL)-derived exosomes in tumor progression and survival. Pharmaceuticals 13, 244.","journal-title":"Pharmaceuticals"},{"key":"2173_CR29","first-page":"153","volume":"15","author":"M Novo","year":"2021","unstructured":"Novo, M., Santambrogio, E., Frascione, P.M.M., Rota-Scalabrini, D., and Vitolo, U. (2021). Antibody therapies for large B-cell lymphoma. Biol: Targets Ther Volume 15, 153\u2013174.","journal-title":"Biol: Targets Ther Volume"},{"key":"2173_CR30","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando, E.J., Han, X., Tribouley, C., Wood, P.A., Leary, R.J., Riester, M., Levine, J.E., Qayed, M., Grupp, S.A., Boyer, M., et al. (2018). Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 24, 1504\u20131506.","journal-title":"Nat Med"},{"key":"2173_CR31","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova, G., and Mraz, M. (2020). The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica 105, 1494\u20131506.","journal-title":"Haematologica"},{"key":"2173_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","volume":"11","author":"H Qin","year":"2018","unstructured":"Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T.J., Ponduri, A., StetlerStevenson, M., Yuan, C.M., Haso, W., Shern, J.F., Shah, N.N., et al. (2018). Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther-Oncol 11, 127\u2013137.","journal-title":"Mol Ther-Oncol"},{"key":"2173_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/pharmaceutics12020194","volume":"12","author":"G Roex","year":"2020","unstructured":"Roex, G., Feys, T., Beguin, Y., Kerre, T., Poir\u00e9, X., Lewalle, P., Vandenberghe, P., Bron, D., and Anguille, S. (2020). Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data. Pharmaceutics 12, 194.","journal-title":"Pharmaceutics"},{"key":"2173_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","volume":"5","author":"D Schneider","year":"2017","unstructured":"Schneider, D., Xiong, Y., Wu, D., N\u00f6lle, V., Schmitz, S., Haso, W., Kaiser, A., Dropulic, B., and Orentas, R.J. (2017). A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. j immunoTher cancer 5, 42.","journal-title":"j immunoTher cancer"},{"key":"2173_CR35","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","volume":"27","author":"N Singh","year":"2021","unstructured":"Singh, N., Frey, N.V., Engels, B., Barrett, D.M., Shestova, O., Ravikumar, P., Cummins, K.D., Lee, Y.G., Pajarillo, R., Chun, I., et al. (2021). Antigen-independent activation enhances the efficacy of 4\u20131BB-costimulated CD22 CAR T cells. Nat Med 27, 842\u2013850.","journal-title":"Nat Med"},{"key":"2173_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13058-020-01380-w","volume":"23","author":"B Sobottka","year":"2021","unstructured":"Sobottka, B., Moch, H., and Varga, Z. (2021). Differential PD-1\/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer. Breast Cancer Res 23, 4.","journal-title":"Breast Cancer Res"},{"key":"2173_CR37","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J.Y., Patel, S., Muffly, L., Hossain, N.M., Oak, J., Baird, J.H., Frank, M.J., Shiraz, P., Sahaf, B., Craig, J., et al. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 27, 1419\u20131431.","journal-title":"Nat Med"},{"key":"2173_CR38","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","volume":"113","author":"DA Thomas","year":"2009","unstructured":"Thomas, D.A., O\u2019Brien, S., Jorgensen, J.L., Cortes, J., Faderl, S., Garcia-Manero, G., Verstovsek, S., Koller, C., Pierce, S., Huh, Y., et al. (2009). Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113, 6330\u20136337.","journal-title":"Blood"},{"key":"2173_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11427-020-1713-9","volume":"64","author":"DD Ti","year":"2020","unstructured":"Ti, D.D., Bai, M.M., Li, X.L., Wei, J.S., Chen, D.Y., Wu, Z.Q., Wang, Y., and Han, W.D. (2020). Adaptive T cell immunotherapy in cancer. Sci China Life Sci 64, 363\u2013371.","journal-title":"Sci China Life Sci"},{"key":"2173_CR40","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2020-140907","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., et al. (2020). Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B cell lymphoma. Blood 136, 1632\u20131644.","journal-title":"Blood"},{"key":"2173_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-021-01120-3","volume":"14","author":"C Wang","year":"2021","unstructured":"Wang, C., Shi, F., Liu, Y., Zhang, Y., Dong, L., Li, X., Tong, C., Wang, Y., Su, L., Nie, J., et al. (2021). Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed\/relapsed after CART19\/20 therapy. J Hematol Oncol 14, 106.","journal-title":"J Hematol Oncol"},{"key":"2173_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0304-3835(01)00758-3","volume":"177","author":"D Xiong","year":"2002","unstructured":"Xiong, D., Xu, Y., Liu, H., Peng, H., Shao, X., Lai, Z., Fan, D., Yang, M., Han, J., Xie, Y., et al. (2002). Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20xanti-CD3 bispecific diabody. Cancer Lett 177, 29\u201339.","journal-title":"Cancer Lett"},{"key":"2173_CR43","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/hum.2018.119","volume":"30","author":"Y Xu","year":"2019","unstructured":"Xu, Y., Li, S., Wang, Y., Liu, J., Mao, X., Xing, H., Tian, Z., Tang, K., Liao, X., Rao, Q., et al. (2019). Induced CD20 expression on B-cell malignant cells heightened the cytotoxic activity of chimeric antigen receptor engineered T cells. Hum Gene Ther 30, 497\u2013510.","journal-title":"Hum Gene Ther"},{"key":"2173_CR44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-021-00309-5","volume":"9","author":"Z Yin","year":"2021","unstructured":"Yin, Z., Zhang, Y., and Wang, X. (2021). Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomark Res 9, 58.","journal-title":"Biomark Res"},{"key":"2173_CR45","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah, E., Lin, M.Y., Silva-Benedict, A., Jensen, M.C., and Chen, Y.Y. (2016). T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res 4, 498\u2013508.","journal-title":"Cancer Immunol Res"},{"key":"2173_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","volume":"36","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Wang, Y., Liu, Y., Tong, C., Wang, C., Guo, Y., Ti, D., Yang, Q., Qiao, S., Wu, Z., et al. (2022). Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a singlearm, phase 1\u20132 trial. Leukemia 36, 189\u2013196.","journal-title":"Leukemia"},{"key":"2173_CR47","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Miao, L., Ren, Z., Tang, F., and Li, Y. (2021). Gene-edited interleukin CAR-T cells therapy in the treatment of malignancies: present and future. Front Immunol 12.","DOI":"10.3389\/fimmu.2021.718686"},{"key":"2173_CR48","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11427-019-9665-8","volume":"63","author":"ZJ Zhao","year":"2020","unstructured":"Zhao, Z.J., Xiao, X.Y., Saw, P.E., Wu. W., Huang, H.Y., Chen J.W., and Nie, Y. (2020). Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci 63, 180\u2013205.","journal-title":"Sci China Life Sci"},{"key":"2173_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.immuni.2010.08.002","volume":"33","author":"X Zhou","year":"2010","unstructured":"Zhou, X., Yu, S., Zhao, D.M., Harty, J.T., Badovinac, V.P., and Xue, H.H. (2010). Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1. Immunity 33, 229\u2013240.","journal-title":"Immunity"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-022-2173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-022-2173-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-022-2173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T20:54:09Z","timestamp":1680728049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-022-2173-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2173"],"URL":"https:\/\/doi.org\/10.1007\/s11427-022-2173-9","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"26 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}